Author

J. Kalashova

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

C. Yang· 3 shared D. Yang· 3 shared G. Lv· 3 shared H. Li· 3 shared H. Liu· 3 shared Q. Shi· 3 shared T. Zhang· 3 shared Y. Long· 3 shared

Activity by Year

2023-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Yang

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MYC amplifies mitotic perturbations elicited by LXY18 to enable synthetic lethality

D. Yang, J. Kalashova, C. Yang, Y. Long, H. Li, S. Zhang, T. Zhang, D. Yu, X. Liu, G. Lv, N. Choudhry, H. Liu, Q. Shi

This study shows that LXY18 selectively kills MYC-overexpressing cancer cells by inducing mitotic arrest, offering a new approach to target MYC-driven tumors.

bioRxiv · Nov 7, 2023 · PreprintCancer Biology

Characterization of mitotic phenotypes associated with a MYC synthetic lethal compound

Q. Shi, X. Liu, J. Kalashova, C. Yang, H. Li, Y. Long, T. Zhang, S. Zhang, G. Lv, J. Huang, H. Liu, J. Zhang, T. D. Allen, D. Yang

This paper characterizes mitotic phenotypes caused by a MYC synthetic lethal compound, dimethylfasudil, showing cell cycle arrest, mitotic catastrophe, and segregation anomalies.

bioRxiv · Apr 3, 2023 · PreprintCancer Biology

An orally bioavailable 4-phenoxy-quinoline compound as a potent AURKB relocation blocker for cancer treatment

D. YANG, J. Li, T. Zhang, Q. Shi, G. Lv, X. Zhou, N. CHOUDHRY, J. Kalashova, C. Yang, H. Li, Y. Long, B. Sakthivel, N. Nimishetti, H. Liu, T. D. Allen, J. Zhang

This paper identifies LXY18, a 4-phenoxy-quinoline compound that blocks AURKB relocalization, showing potent antimitotic activity and oral bioavailability.

bioRxiv · Jan 29, 2023 · PreprintCancer Biology